Artelo Biosciences Stock Current Valuation
| ARTL Stock | USD 1.04 0.05 5.05% |
Valuation analysis of Artelo Biosciences helps investors to measure Artelo Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is expected to rise to -0.12 this year. Enterprise Value Multiple is expected to rise to -0.12 this year. Fundamental drivers impacting Artelo Biosciences' valuation include:
Undervalued
Today
Please note that Artelo Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Artelo Biosciences is based on 3 months time horizon. Increasing Artelo Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Artelo stock is determined by what a typical buyer is willing to pay for full or partial control of Artelo Biosciences. Since Artelo Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Artelo Stock. However, Artelo Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.04 | Real 2.0 | Target 5.0 | Hype 1.0 | Naive 1.16 |
The intrinsic value of Artelo Biosciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Artelo Biosciences' stock price.
Estimating the potential upside or downside of Artelo Biosciences helps investors to forecast how Artelo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Artelo Biosciences more accurately as focusing exclusively on Artelo Biosciences' fundamentals will not take into account other important factors: Artelo Biosciences Company Current Valuation Analysis
Artelo Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Artelo Biosciences Current Valuation | 882.98 K |
Most of Artelo Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Artelo Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Artelo Biosciences is extremely important. It helps to project a fair market value of Artelo Stock properly, considering its historical fundamentals such as Current Valuation. Since Artelo Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artelo Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artelo Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Artelo Biosciences has a Current Valuation of 882.98 K. This is 99.99% lower than that of the Pharmaceuticals sector and 99.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Artelo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artelo Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics of similar companies.Artelo Biosciences is currently under evaluation in current valuation category among its peers.
Artelo Fundamentals
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 882.98 K | ||||
| Shares Outstanding | 3.28 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 1.05 % | ||||
| Number Of Shares Shorted | 13.42 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 1.09 X | ||||
| EBITDA | (7.44 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | 0.87 X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (3.05) X | ||||
| Target Price | 5.33 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 3.24 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
| Net Asset | 4.7 M |
About Artelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Artelo Biosciences Piotroski F Score and Artelo Biosciences Altman Z Score analysis. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.